title: The value of visfatin in the prediction of metabolic syndrome: a multi-factorial analysis.
abstract: We describe the adipokine concentration in patients with metabolic syndrome, stressing the role of visfatin. A cross-sectional single center study on 70 patients with metabolic syndrome plus 76 controls was performed. Patients with metabolic syndrome had higher visfatin levels compared to controls, following adjustments for age, sex, waist/hip circumference, systolic, and diastolic blood pressure, fasting plasma glucose (FPG), HbA1c, body mass index, and homeostasis model assessment of insulin resistance (HOMA-IR) [(5.39 ± 0.29 vs. 3.88 ± 0.32); F(1, 129) = 10.8, P < 0.01]. A logistic regression analysis revealed that circulating visfatin levels and HbA1c were the top variables for predicating metabolic syndrome. In patients with metabolic syndrome, visfatin did not correlate with any of the measured variables, with the single exception of adiponectin; in patients without metabolic syndrome, circulating visfatin levels were significantly associated with FPG, HbA1c, insulin, HOMA-IR, HDL, and triglyceride. These findings may contribute to our current knowledge about visfatin in metabolic syndrome.
authors.affiliation: Endocrinology and Metabolism Research Center, Vali-Asr Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. esteghamati@tums.ac.ir
authors.forename: Alireza
authors.initials: A
authors.lastname: Esteghamati
authors.forename: Afsaneh
authors.initials: A
authors.lastname: Morteza
authors.forename: Ali
authors.initials: A
authors.lastname: Zandieh
authors.forename: Samira
authors.initials: S
authors.lastname: Jafari
authors.forename: Mehdi
authors.initials: M
authors.lastname: Rezaee
authors.forename: Manouchehr
authors.initials: M
authors.lastname: Nakhjavani
authors.forename: Arsia
authors.initials: A
authors.lastname: Jamali
authors.forename: Abdoul-Reza
authors.initials: AR
authors.lastname: Esteghamati
authors.forename: Omid
authors.initials: O
authors.lastname: Khalilzadeh
mesh_terms: D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000032:analysis; D016022:Case-Control Studies; D003430:Cross-Sectional Studies; D016207:Cytokines / Q000097:blood*; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D007492:Iran; D016014:Linear Models; D008075:Lipoproteins, HDL / Q000097:blood; D016015:Logistic Models; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood* / Q000175:diagnosis / Q000503:physiopathology; D008875:Middle Aged; D015999:Multivariate Analysis; D054409:Nicotinamide Phosphoribosyltransferase / Q000097:blood*; D016017:Odds Ratio; D011237:Predictive Value of Tests; D018570:Risk Assessment; D012307:Risk Factors; D014280:Triglycerides / Q000097:blood; D015854:Up-Regulation
chemical_list: D015415:Biomarkers; D001786:Blood Glucose; D016207:Cytokines; D006442:Glycated Hemoglobin; D007328:Insulin; D008075:Lipoproteins, HDL; D054409:Nicotinamide Phosphoribosyltransferase; D014280:Triglycerides; C517652:hemoglobin A1c protein, human; C085455:nicotinamide phosphoribosyltransferase, human